BerGenBio

Selective AXL inhibitors

Home  /  Investors

Investors

Yearly Reports

Annual Report 2021

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Corporate Presentation

ABGSE Life Science Summit

18 May 2022

Read More

Share price

BerGenBio ASA

BGBIO (Norway: Oslo)

Share Price Chart

News

Latest News

BERGENBIO ANNOUNCES LAUNCH OF BUSINESS STRATEGY FOCUSED ON NSCLC AND COVID-19

BERGENBIO ANNOUNCES COMPLETE DATA ANALYSIS OF ACCORD2 PHASE II BEMCENTINIB STUDY IN HOSPITALIZED COVID-19 PATIENTS – PRIMARY EFFICACY ENDPOINT MET

BERGENBIO PRESENTS BEMCENTINIB COVID-19 CLINICAL TRIAL DATA AT ECCMID 2022

More News

Scientific Presentations

ECCMID 2022, Jaya Nautiyal et al.

25 April 2022

Read More

Annual Report 2021

BerGenBio (OSE:BGBIO) is a clinical-stage biopharmaceutical company developing innovative drugs for aggressive diseases, including immune evasive, drug resistant and metastatic cancers.

Our annual report

Events

Upcoming Events

  Annual General Meeting April 28th

  Q1 2022 Results May 24, 2022

BERGENBIO ASA: Invitation to THIRD quarter 2021 results

BERGENBIO ASA: Invitation to PRESENTATION OF SECOND quarter and HALF YEAR 2021 results

BERGENBIO TO PRESENT AT ABGSC SEMINAR

More Events

Subscribe to our newsletter

Please remember to confirm your email by clicking on the link provided in the subscription confirmation email. We will save your name and email address with the sole purpose of sending information regarding our latest news and events. By subscribing to BerGenBio’s newsletter you consent to our Privacy Policy and Terms of Use.